Adenosine is a signaling nucleoside that has been proposed to contribute to the pathogenesis of asthma and chronic obstructive pulmonary disease. Previous studies suggest that adenosine might play an important role in modulating levels of inflammatory mediators in the lung. Because airway epithelium is an important cellular source of inflammatory mediators, the objective of the present study was to determine whether adenosine affects the expression and release of inflammatory cytokines from human bronchial epithelial cells (HBECs). Among the four subtypes of adenosine receptors, the A 2B receptor was expressed at the highest level. 
to the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD) (3) . This hypothesis is based on the findings that the interstitial concentration of adenosine is elevated in the lungs of individuals with asthma (4) and inhaled adenosine causes bronchoconstriction in patients with asthma (5) . The bronchoconstrictive effect of adenosine has been attributed to the activation of lung mast cells (6, 7) . In addition to the mast cells (8, 9) , adenosine has been found to modulate the functions of other inflammatory cells such as lymphocytes (10) , eosinophils (11, 12) , neutrophils (13) , and macrophages (14) , and lung cells such as bronchial smooth muscle cells (15, 16) and fibroblasts (17) . The physiologic effects of adenosine on lung epithelial cells have also been investigated. Adenosine is able to modulate the activity of ion channels (18) (19) (20) , and induce fibronectin (21) and mucin gene expression (22) . However, it is unknown whether and how adenosine affects the release of inflammatory cytokines from epithelial cells and epithelial cell-inflammatory cell communication.
In this study, we used the primary cultured human bronchial epithelial cells (HBECs) as the model system. The objectives of this study were to determine (1 ) whether adenosine affects the release of inflammatory cytokines from bronchial epithelial cells, (2 ) what the potential effects of these cytokines on lung inflammation might be, and (3 ) which adenosine receptor subtype is responsible for the effect of adenosine.
MATERIALS AND METHODS

Materials
A selective antagonist to the A 2B receptor (CVT-6694) was synthesized by the Department of Bio-Organic Chemistry at CV Therapeutics Inc. (Palo Alto, CA), and was described in our previous publication (15) . All other reagents, such as rolipram, forskolin, 5Ј-(N-ethylcarboxamido)-adenosine (NECA), and adenosine deaminase (ADA), were purchased from Sigma (St. Louis, MO) unless otherwise stated.
Cell Culture
Primary cultured normal HBECs were obtained from Clonetics (San Diego, CA) and cultured using bronchial epithelial cell growth medium (Clonetics). HBECs were routinely grown in a humidified incubator with 5% CO 2 at 37ЊC. Cells from three different donors and from passages 2-3 were used in the following studies. THP-1 cells were purchased from ATCC (Manassas, VA) and cultured according to ATCC's instructions.
Stimulation of HBECs
HBECs were seeded into 12-well tissue culture plates at a density of 1 ϫ 10 5 cells/well and allowed to adhere overnight and reach ‫ف‬ 90% confluence. Cells were washed twice in HEPES-buffered saline, and cultured in bronchial epithelial cell basal medium (Clonetics) containing various agonists or antagonists of AdoRs for 1 or 24 h.
RNA Extraction and Real-Time RT-PCR
Total RNA was extracted from HBECs using the Stratagene Absolutely RNA RT-PCR Miniprep Kit (Stratagene Corp., La Jolla, CA) followed by DNase treatment to eliminate potential genomic DNA contamination. Real-time RT-RCR for adenosine receptors was performed as previously described (15) . Specific primers for IL-19 (forward: 5Ј-AAA CAATCTCCCCAAGGTGGAT-3Ј; reverse: 5Ј-AGGAAATGCTGT CAAGGTTTGC-3Ј), GRO-␤ (forward: 5Ј-TTTCTTCGTGATGACA TATCACATGT-3Ј; reverse: 5Ј-TCCTCAGCCTCTATCACAGTGG-3Ј), and GRO-␥ (forward: 5Ј-TGCTTGTAGGGCATAATGCCT-3Ј; reverse: 5Ј-GGGAAAGAGAAACGCTGCAG-3Ј) were designed using Primer Express 2.0 (Applied Biosystems, Foster City, CA) following the recommended guidelines based on sequences from GenBank. At the end of the PCR cycle, a dissociation curve was generated to ensure the amplification of a single product, and the threshold cycle times (Ct values) for each gene were determined. Relative mRNA levels were calculated based on the Ct values, normalized to ␤-actin in the same sample, and presented as percentages of ␤-actin mRNA.
Measurement of cAMP Accumulation
Cells were harvested using 0.0025% trypsin and 2 mM EDTA in PBS, washed and resuspended in phenol-free DMEM to a concentration of 5 ϫ 10 5 cells/ml, and then incubated with 1 U/ml of ADA for 30 min at room temperature. Cells were then treated with AdoR agonists, antagonists, and forskolin in the presence of 50 M of the phosphodiesterase IV inhibitor, rolipram. After incubating for 15 min at 37ЊC, cells were lysed and cAMP concentrations were determined using cAMPScreen Direct System (Applied Biosystems) according to the manufacturer's instructions.
cDNA Array Analysis
Expression of inflammatory cytokines was determined using a cDNA array kit (Cat. No. HS-033; SuperArray, Frederick, MD). The assay was performed according to manufacturer's instructions. Biotinylated cDNA probes were generated from 1-2 g of total RNA using GEArray RT-labeling enzyme kit (SuperArray). The labeled cDNA probes were then hybridized with gene-specific cDNA fragments spotted on nylon membrane. The signals were detected with the chemiluminescent detection reagents. The relative expression level of each gene was analyzed using GEArray analysis software (SuperArray).
Measurement of IL-19 and TNF-␣
ELISA for IL-19 was developed according to manufacturer's protocol (R&D Systems, Minneapolis, MN). Plates (96-well) were pre-coated with 50 ng/well anti-human IL-19 Ab (R&D Systems). IL-19 was detected using 100 ng/ml of biotinylated polyclonal IL-19 Ab (R&D systems), streptavidin-HRP, and TMB (tetramethylbenzidine) chromogen (Biosource, Camarillo, CA). Serial dilutions of recombinant human IL-19 (rhIL-19; PeproTech, Rocky Hill, NJ) was used as standard. The detection limit of rhIL-19 was 0.2 ng/ml. The concentrations of TNF-␣ in the cell medium were determined using ELISA kits obtained from Biosource according to the manufacturer's instructions. The minimal detection level of TNF-␣ with these kits was 1.7 pg/ml.
Statistical Analysis
Data are presented as mean Ϯ SEM of at least three separate experiments. The statistical analysis was performed using ANOVA followed by Bonferroni test. A P value of Ͻ 0.05 was considered significant.
RESULTS
Expression of AdoR Subtypes in HBECs
Real-time RT-PCR was performed to quantify the levels of transcripts for AdoRs. Among the four subtypes, the A 2B receptor had the highest transcript level (0.49 Ϯ 0.04% of ␤-actin expression) ( Figure 1 ). Lower levels of A 1 and A 2A receptor transcripts were also detected (0.0012 Ϯ 0.0002% and 0.0058 Ϯ 0.0003% of ␤-actin, respectively), whereas the transcript for A 3 receptors was below the detection level. Hence, the rank order of AdoR mRNA levels was
In many cell types, activation of A 2A or A 2B receptors leads to increases in cellular cAMP accumulation, whereas activation of A 1 or A 3 receptors decreases cellular cAMP accumulation caused by the adenylate cyclase activator, forskolin. To identify the AdoR subtype(s) that are functionally expressed in HBECs, the effects of a nonselective agonist NECA and several other selective agonists on cellular cAMP accumulation were deter- mined. NECA is a stable analog of adenosine, and it activates all four AdoR subtypes including A 2B receptors. As shown in Figure 2A , NECA increased cellular cAMP accumulation in a concentration-dependent manner, with potency (EC 50 value) of 8.8 Ϯ 1.3 M. In contrast, the A 2A -selective agonist CGS-21680 (р 10 M) did not cause a significant increase in cellular cAMP concentration. In addition, the A 1 -selective agonist, CPA (1 M), and the A 3 -selective agonist, IB-MECA (1 M), failed to inhibit the cellular cAMP accumulation caused by forskolin (10 M, Figure 2B ). Because there is no selective agonist for A 2B receptors, the effect of a selective antagonist to A 2B receptors, CVT-6694, on NECA-induced cellular cAMP accumulation was determined. CVT-6694 has a high affinity for the A 2B receptor (K i ϭ 7 nM) and very low affinity for three other AdoR subtypes (K i values are Ͼ 5 M for A 1, A 2A, and A 3 receptors) (15, 17) . As shown in Figure 2A , CVT-6694 (1 M) significantly attenuated NECA-induced cellular cAMP accumulation. Thus, using cellular cAMP concentration as readout for the functional expression of AdoRs, the results indicate that A 2B receptors are functionally expressed in HBECs, whereas A 1, A 2A, or A 3 receptors are not.
Effects of NECA on Expression of Inflammatory Cytokines
The effect of NECA on the gene expression of the inflammatory cytokines was determined using a cDNA array containing 85 inflammatory genes involved in asthma. Among the 85 genes on the microarray, GRO-␤, GRO-␥, and IL-19 genes were increased above 2-fold by NECA (data not shown).
To confirm and quantify NECA-induced expression of GRO-␤, GRO-␥, and IL-19, gene-specific real-time RT-PCR was performed on HBECs treated with NECA (10 M) for 1 h. As shown in Figure 3 , NECA increased mRNA expression of IL-19, GRO-␤, and GRO-␥ up to 4.3-Ϯ 0.9-, 5.6-Ϯ 0.6-, and 4.3-Ϯ 0.6-fold above control levels, respectively. Figure 5A ). In contrast, GRO-␤ (100 ng/ml), GRO-␥ (100 ng/ml), or NECA (10 M) alone had no significant effect on TNF-␣ release from THP-1 cells ( Figure 5A ). These data demonstrate that IL-19, but not NECA or GRO-␤/␥, was able to activate THP-1 cells. Furthermore, the conditional media collected from HBECs treated with vehicle (control-M) or NECA (NECA-M) for 24 h were used to incubate THP-1 cells for an additional 24 h. NECA-M caused a 4.6-Ϯ 1.0-fold increase in TNF-␣ release from THP-1 cells compared with control-M. This effect was completely abolished by an IL-19-neutralizing Ab ( Figure 5B ). These results suggest that IL-19 released from NECA-stimulated HBECs is able to and sufficient to activate THP-1 cells.
Effects of TNF-␣ on Expression of AdoRs in HBECs
To further explore the interaction between epithelial cells and monocytes, the effect of TNF-␣ on AdoR expression in HBECs was determined using real-time RT-PCR. TNF-␣ caused a significant time-dependent increase in mRNA expression of A 2B receptors ( Figure 6 ). After 24 h incubation with TNF-␣, mRNA level of A 2B receptors was increased to 3.1 Ϯ 0.3 fold above basal levels ( Figure 6 ). Incubation of TNF-␣ for 5 and 24 h also significantly upregulated the mRNA levels of A 1 and A 2A receptors up to 2.0-Ϯ 0.3-and 1.6-Ϯ 0.1-fold above basal levels, although the expression of both subtypes of receptors was still very low (below 0.01% of ␤-actin mRNA level). The mRNA expression of the A 3 receptors remained below the detection level after TNF-␣ treatment ( Figure 6 ).
DISCUSSION
The main objective of this study was to determine the effect of adenosine on the inflammatory responses mediated by epithelial cells. The main findings of our study are: (1 ) A 2B receptors are the predominant subtype of AdoRs expressed in primary HBECs; (2 ) activation of A 2B receptors on HBECs increases the release of IL-19, which is able to and sufficient to induce TNF-␣ production from human monocytes; and (3 ) TNF-␣ can upregulate the expression of A 2B receptors in HBECs. These findings support the hypothesis that adenosine can initiate and amplify inflammatory responses which might be important in pathogenesis of inflammatory lung diseases. Among the four subtypes of AdoRs, the A 2B receptor has the lowest affinity for the natural ligand, adenosine, requiring at least micromolar concentrations of adenosine for its activation (23) . Hence, under normal physiologic conditions, adenosine levels might be too low to activate the A 2B receptor. However, higher levels of adenosine have been detected during hypoxia, ischemia, and inflammation (24) (25) (26) . In addition, results of recent studies (16, 17, 26, 27) suggest the A 2B receptor expression can markedly increase during inflammation and hypoxia. The molecular mechanism of how A 2B receptor expression is modulated during inflammation is largely unknown. The results of the current study demonstrate that TNF-␣, a well-known inflammatory marker and mediator, upregulates the expression of A 1 , A 2A , and A 2B receptors in HBECs. This is consistent with an earlier report suggesting that TNF-␣ regulates the expression of A 2A and A 2B receptors in microvascular endothelial cells (28) .
It should be noted that the expression of A 2B receptors are upregulated in the lung of ragweed-challenged mice (27) and IL-13-transgenic mice (26) . More strikingly, increased expression of A 2B receptors in the lung of IL-13-transgenic mice has been localized in bronchial epithelium. On the other hand, results of a recent study suggested that the density of A 2B receptor, determined using saturation binding assays with an antagonist radioligand, was significantly decreased in the lungs of patients with COPD compared with the control group, whereas the radioligand affinity for A 2B receptors was not altered (29) . However, it is not entirely clear which cells contribute to the decrease of A 2B receptors in COPD, how the expression of A 2B receptor is regulated in allergic diseases versus COPD, and the precise role of A 2B receptor in these diseases. Interestingly, in the same study, the expression level of the A 2B receptor was found to be highest in mast cells and macrophages. Regardless, the authors concluded that the A 2B receptor might play an important role in the pathogenesis of COPD. Therefore, future studies to determine the effect of A 2B antagonist in COPD would be of interest.
Functional expression of the A 2B receptor in airway epithelial cells has been reported. This receptor has been shown to mediate adenosine-modulated ion transport (18, 19) ; however, the function of A 2B receptor in mediating cytokine release is not known. The results of our study showed that activation of A 2B receptors upregulates the expression of proinflammatory cytokines such as IL-19, GRO-␤, and GRO-␥. GRO-␤ (CXCL2) and GRO-␥ (CXCL3) are CXC chemokines. The functions of these two chemokines are similar to IL-8 (CXCL8), which belongs to the same chemokine family. GRO-␤ and GRO-␥ chemoattract and activate neutrophils (30) , and promote angiogenesis by activating the CXCR2 receptor on endothelial cells (31) . Because neutrophils have been implicated in the pathogenesis of inflammatory lung diseases including asthma and COPD, and because CXC chemokine-mediated angiogenesis is associated with idiopathic pulmonary fibrosis (32), CXCR2 is a potential therapeutic target for these diseases. A more important finding of the present study is that NECA increases the release of IL-19 from HBECs. IL-19 belongs to the IL-10 family, which includes IL-10, IL-19, IL-20, IL-22, IL-24, and IL-26 (33) . In contrast to the pleiotropic role of IL-10, IL-19 has been shown to have mainly proinflammatory roles. IL-19 stimulates T cells to produce IL-4 and IL-13 (34) and alters the balance of Th1/Th2 in favor of Th2. IL-19 also induces production of IL-6, TNF-␣, and reactive oxygen species from mouse monocytes (35) . IL-19 level is elevated in the serum of patients with asthma compared with healthy control subjects, and its transcript is also increased in the lung of an allergen-challenged mouse model (34) . Because adenosine is elevated in the asthmatic lung to hundred-micromolar range (4), and at this level it can increase the release of IL-19 from HBECs (data not shown), it is plausible to postulate that elevated adenosine in the asthmatic lung may contribute to the elevation of IL-19. Interestingly, recent studies have shown that elevated adenosine play a key role in the upregulation of IL-13 and several other cytokines in mouse models of pulmonary diseases (26) .
Consistent with earlier reports on the proinflammatory roles of IL-19, the results of our study demonstrate that IL-19 released by bronchial epithelial cells can activate human monocytes. In the present study, conditional medium of NECA-stimulated HBECs was able to activate THP-1 cells. This effect is not due to the activation of AdoRs on THP-1 cells, because this effect was completely abolished by the IL-19-neutralizing Ab and NECA alone did not stimulate TNF-␣ production from THP-1 cells. Furthermore, the results in this study suggest that elevated TNF-␣ could have a positive feedback on the expression of the adenosine receptors on the epithelial cells. Hence, adenosine may play an important role in the interaction between epithelial cells and inflammatory cells in the airway.
Activation of the A 2B receptor increases cAMP, which is generally believed to elicit anti-inflammatory responses. However, proinflammatory roles of this receptor have been reported (36) . For example, in human mast cells (HMC-1), activation of A 2B receptors increase cAMP (37) and also increase the release of IL-4, IL-8, and IL-13 (8) . A possible explanation is that A2B receptor can couple to other cell signaling pathways, such as Ca/PLC, and MAP kinases (38) , and these pathways are likely to mediate the proinflammatory effect of adenosine or adenosine analog via activation of A 2B receptors. However, it remains to be established which signaling pathway is responsible for the A 2B -mediated upregulation of IL-19. It should be noted that antiinflammatory roles of the A 2B receptor have also been reported in other in vitro studies (39) (40) (41) . Therefore, further studies using animal models or patients will be helpful to determine the role of A 2B receptors in the lung.
In summary, adenosine, IL-19, and TNF-␣ are important proinflammatory mediators in lung inflammation. These mediators may interact with one another to cause the alleviation or exacerbation of the disease. The results of the present study demonstrated that the A 2B receptor subtype is the predominant AdoR expressed in HBECs. Activation of this AdoR subtype increased the release of IL-19. IL-19 released from these cells, in turn, stimulated the human monocytes to release TNF-␣. TNF-␣ is able to upregulate the expression of A 2B receptors in HBECs (Figure 7) . Thus, our findings provide a novel mechanism that could explain the interactions among adenosine, IL-19, and TNF-␣ in the initiation, maintenance, and amplification of inflammatory responses. In addition, our findings suggest that the A 2B receptor might be a novel therapeutic target for inflammatory lung diseases.
